117 related articles for article (PubMed ID: 12495908)
21. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
22. Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
Irvine DA; Shepherd JD
Bone Marrow Transplant; 2009 Aug; 44(4):267-8. PubMed ID: 19234506
[No Abstract] [Full Text] [Related]
23. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
24. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
[TBL] [Abstract][Full Text] [Related]
25. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
[TBL] [Abstract][Full Text] [Related]
26. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
27. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
29. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
Ruiz-Argüelles GJ
Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
[No Abstract] [Full Text] [Related]
30. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
[TBL] [Abstract][Full Text] [Related]
32. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
33. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
34. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
[TBL] [Abstract][Full Text] [Related]
35. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
36. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R
Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052
[No Abstract] [Full Text] [Related]
38. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
Tefferi A
Cancer; 2011 Jan; 117(2):234-7. PubMed ID: 21210471
[No Abstract] [Full Text] [Related]
39. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
[No Abstract] [Full Text] [Related]
40. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
